News & Updates

Show Multimedia Only

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025 by

Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025

Vericiguat misses endpoint in HFrEF trial

12 Sep 2025

In the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and no recent worsening, the use of vericiguat falls short of reducing the risk of the composite of cardiovascular death and HF hospitalization, as shown in a phase III study.

Vericiguat misses endpoint in HFrEF trial

12 Sep 2025

Oral pharmaceutical LSD formulation beneficial in generalized anxiety disorder

11 Sep 2025 by

A single administration of MM120, a semisynthetic pharmaceutical formulation of lysergic acid diethylamide (LSD), helps ease symptoms in patients with moderate to severe generalized anxiety disorder (GAD), as shown in a phase IIB study.

Oral pharmaceutical LSD formulation beneficial in generalized anxiety disorder

11 Sep 2025

Adjuvant chemotherapy predicts worse DFS in endometrial cancer

11 Sep 2025

In patients with surgically unresectable endometrial cancer who underwent neoadjuvant chemoradiation (CRT) or radiation therapy (RT), adjuvant chemotherapy is associated with worse DFS but not with improved OS, reveals a recent study.

Adjuvant chemotherapy predicts worse DFS in endometrial cancer

11 Sep 2025

Semaglutide safe for schizophrenia patients with prediabetes, obesity

11 Sep 2025

Weekly treatment with semaglutide yields reductions in HbA1c and weight in schizophrenia patients with prediabetes and obesity without worsening mental health, according to a study.

Semaglutide safe for schizophrenia patients with prediabetes, obesity

11 Sep 2025

Common blood test predicts which AD patients will have rapid cognitive decline

11 Sep 2025 by

Insulin resistance, detected through the routine triglyceride-glucose (TyG) index, identifies individuals with early Alzheimer’s disease (AD) who are four times more likely to experience rapid cognitive decline, findings from a new study presented at EAN 2025 suggest.

Common blood test predicts which AD patients will have rapid cognitive decline

11 Sep 2025

Sotrovimab for COVID-19 pneumonia lowers risk of death in specific subgroup

10 Sep 2025 by

In the treatment of hospitalized patients with COVID-19 pneumonia, the use of the neutralizing monoclonal antibody sotrovimab in addition to usual care reduces mortality but only in the subgroup of those with a high baseline serum SARS-CoV-2 antigen concentration, according to the open-label RECOVERY trial.

Sotrovimab for COVID-19 pneumonia lowers risk of death in specific subgroup

10 Sep 2025

Mirikizumab enhances life quality, productivity of CD patients

10 Sep 2025 by

The use of mirikizumab has improved work productivity and health-related quality of life (HRQoL) in patients with moderately to severely active Crohn’s disease (CD) by week 12, a study has shown. These improvements have been maintained for a year.

Mirikizumab enhances life quality, productivity of CD patients

10 Sep 2025

First-line NIVO plus IPI shows ORR, OS benefit in patients with HCC

10 Sep 2025 by

Among Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC), treatment with nivolumab plus ipilimumab (NIVO + IPI) showed better objective response rate (ORR) and overall survival (OS) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting, according to the CheckMate 9DW expanded analysis presented at ESMO GI 2025.

First-line NIVO plus IPI shows ORR, OS benefit in patients with HCC

10 Sep 2025

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

09 Sep 2025 by

In patients with established coronary artery disease (CAD), clopidogrel appears to provide superior protection against major adverse cardiovascular or cerebrovascular events (MACCE) without increasing the risk of bleeding when compared with aspirin, according to a meta-analysis.

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

09 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

Vericiguat misses endpoint in HFrEF trial

Vericiguat misses endpoint in HFrEF trial

Oral pharmaceutical LSD formulation beneficial in generalized anxiety disorder

Oral pharmaceutical LSD formulation beneficial in generalized anxiety disorder

Adjuvant chemotherapy predicts worse DFS in endometrial cancer

Adjuvant chemotherapy predicts worse DFS in endometrial cancer

Semaglutide safe for schizophrenia patients with prediabetes, obesity

Semaglutide safe for schizophrenia patients with prediabetes, obesity

Common blood test predicts which AD patients will have rapid cognitive decline

Common blood test predicts which AD patients will have rapid cognitive decline

Sotrovimab for COVID-19 pneumonia lowers risk of death in specific subgroup

Sotrovimab for COVID-19 pneumonia lowers risk of death in specific subgroup

Mirikizumab enhances life quality, productivity of CD patients

Mirikizumab enhances life quality, productivity of CD patients

First-line NIVO plus IPI shows ORR, OS benefit in patients with HCC

First-line NIVO plus IPI shows ORR, OS benefit in patients with HCC

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD

Meta-analysis favours clopidogrel over aspirin for secondary prevention in CAD